Shares of Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $80.70.
A number of research firms have recently issued reports on IMCR. Oppenheimer reiterated an “outperform” rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. JPMorgan Chase & Co. dropped their price target on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, August 28th. Mizuho lowered their price objective on shares of Immunocore from $90.00 to $88.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $81.00 target price on shares of Immunocore in a research note on Friday, August 9th.
Check Out Our Latest Analysis on IMCR
Hedge Funds Weigh In On Immunocore
Immunocore Price Performance
NASDAQ IMCR opened at $33.40 on Monday. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore has a 12-month low of $33.04 and a 12-month high of $76.98. The company has a market capitalization of $1.67 billion, a PE ratio of -27.38 and a beta of 0.73. The firm’s 50 day moving average is $37.57 and its 200-day moving average is $48.96.
Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company had revenue of $75.40 million for the quarter, compared to the consensus estimate of $74.58 million. During the same period last year, the company earned ($0.37) earnings per share. The firm’s revenue was up 26.2% compared to the same quarter last year. Equities research analysts anticipate that Immunocore will post -1.79 earnings per share for the current fiscal year.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Recommended Stories
- Five stocks we like better than Immunocore
- What are earnings reports?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.